Shire May Split Up – But Punting On Bigger Decisions For Now
The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.
You may also be interested in...
Before the March 28 announcement of Takeda’s interest in buying Shire, the focus of Shire’s first quarter earnings call was expected to be the initial reporting of financial results for rare disease and neuroscience as separate units. Sales for the former grew, but declined for the latter.
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.